Level C· Early human research exploring benefitsProspective StudyPubMed

Inflammatory Pre-Conditioning of Adipose-Derived Stem Cells with Cerebrospinal Fluid from Traumatic Brain Injury Patients Alters the Immunomodulatory Potential of ADSC Secretomes.

Üçal M., Maurer C., Etschmaier V., Hamberger D., Grünbacher G., Tögl L.

Prospective Study on Chronic Inflammation, Immune Modulation, published in J Neurotrauma (2021) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Neurotrauma (2021)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
33514282
DOI
10.1089/neu.2020.7017
Citations
3

Abstract (original English)

Immunomodulation by adipose-tissue-derived stem cells (ADSCs) is of special interest for the alleviation of damaging inflammatory responses in central nervous system injuries. The present study explored the effects of cerebrospinal fluid (CSF) from traumatic brain injury (TBI) patients on this immunomodulatory potential of ADSCs. CSF conditioning of ADSCs increased messenger RNA levels of both pro- and anti-inflammatory genes compared to controls. Exposure of phorbol-12-myristate-13-acetate-differentiated THP1 macrophages to the secretome of CSF-conditioned ADSCs downregulated both proinflammatory (cyclooxygenase-2, tumor necrosis factor alpha) and anti-inflammatory (suppressor of cytokine signaling 3, interleukin-1 receptor antagonist, and transforming growth factor beta) genes in these cells. Interleukin-10 expression was elevated in both naïve and conditioned secretomes. ADSC secretome treatment, further, induced macrophage maturation of THP1 cells and increased the percentage of CD11b + , CD14 + , CD86 + , and, to a lesser extent, CD206 + cells. This, moreover, enhanced the phagocytic activity of CD14 + and CD86 + cells, though independently of pre-conditioning. Secretome exposure, finally, also induced a reduction in the percentage of CD192 + adherent cells in cultures of peripheral blood mononuclear cells (PBMCs) from both healthy subjects and TBI patients. This limited e

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AdultAgedBrain Injuries, TraumaticCase-Control StudiesCell Culture TechniquesCerebrospinal FluidCulture Media, ConditionedFemaleHumansInflammation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research